Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
This study includes the clinicopathological and biological analysis of several T-UCRs such as Uc.416+A, Uc.160+, Uc.63+, Uc.416+A in gastrointestinal or urological cancer. We clarified the machanism of drug-resistance, the effect on other molecules such as miR-153 or PTEN, and the induction of EMT by these T-UCRs. In addition, we showed that claspin and RCAN2 enhance the ability of proliferation and invasiveness, and both of them are poor prognostic factors and play a crucial role in tumor progression.
|